Magrolimab is under investigation in clinical trial NCT02953782 (Trial of Magrolimab (Hu5f9-g4) in Combination With Cetuximab in Participants With Solid Tumors and Advanced Colorectal Cancer).
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Diethylstilbestrol | Diethylstilbestrol may increase the thrombogenic activities of Magrolimab. |
| Chlorotrianisene | Chlorotrianisene may increase the thrombogenic activities of Magrolimab. |
| Conjugated estrogens | Conjugated estrogens may increase the thrombogenic activities of Magrolimab. |
| Estrone | Estrone may increase the thrombogenic activities of Magrolimab. |
| Estradiol | Estradiol may increase the thrombogenic activities of Magrolimab. |
| Dienestrol | Dienestrol may increase the thrombogenic activities of Magrolimab. |
| Ethinylestradiol | Ethinylestradiol may increase the thrombogenic activities of Magrolimab. |
| Mestranol | Mestranol may increase the thrombogenic activities of Magrolimab. |
| Estriol | Estriol may increase the thrombogenic activities of Magrolimab. |
| Estrone sulfate | Estrone sulfate may increase the thrombogenic activities of Magrolimab. |
| Quinestrol | Quinestrol may increase the thrombogenic activities of Magrolimab. |
| Hexestrol | Hexestrol may increase the thrombogenic activities of Magrolimab. |
| Tibolone | Tibolone may increase the thrombogenic activities of Magrolimab. |
| Synthetic Conjugated Estrogens, A | Synthetic Conjugated Estrogens, A may increase the thrombogenic activities of Magrolimab. |
| Synthetic Conjugated Estrogens, B | Synthetic Conjugated Estrogens, B may increase the thrombogenic activities of Magrolimab. |
| Polyestradiol phosphate | Polyestradiol phosphate may increase the thrombogenic activities of Magrolimab. |
| Esterified estrogens | Esterified estrogens may increase the thrombogenic activities of Magrolimab. |
| Zeranol | Zeranol may increase the thrombogenic activities of Magrolimab. |
| Equol | Equol may increase the thrombogenic activities of Magrolimab. |
| Promestriene | Promestriene may increase the thrombogenic activities of Magrolimab. |
| Methallenestril | Methallenestril may increase the thrombogenic activities of Magrolimab. |
| Epimestrol | Epimestrol may increase the thrombogenic activities of Magrolimab. |
| Moxestrol | Moxestrol may increase the thrombogenic activities of Magrolimab. |
| Estradiol acetate | Estradiol acetate may increase the thrombogenic activities of Magrolimab. |
| Estradiol benzoate | Estradiol benzoate may increase the thrombogenic activities of Magrolimab. |
| Estradiol cypionate | Estradiol cypionate may increase the thrombogenic activities of Magrolimab. |
| Estradiol valerate | Estradiol valerate may increase the thrombogenic activities of Magrolimab. |
| Biochanin A | Biochanin A may increase the thrombogenic activities of Magrolimab. |
| Formononetin | Formononetin may increase the thrombogenic activities of Magrolimab. |
| Estetrol | Estetrol may increase the thrombogenic activities of Magrolimab. |
| Cetuximab | The risk or severity of adverse effects can be increased when Cetuximab is combined with Magrolimab. |
| Human immunoglobulin G | The risk or severity of adverse effects can be increased when Human immunoglobulin G is combined with Magrolimab. |
| Omalizumab | The risk or severity of adverse effects can be increased when Omalizumab is combined with Magrolimab. |
| Adalimumab | The risk or severity of adverse effects can be increased when Adalimumab is combined with Magrolimab. |
| Abciximab | The risk or severity of adverse effects can be increased when Abciximab is combined with Magrolimab. |
| Gemtuzumab ozogamicin | The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Magrolimab. |
| Indium In-111 satumomab pendetide | The risk or severity of adverse effects can be increased when Indium In-111 satumomab pendetide is combined with Magrolimab. |
| Infliximab | The risk or severity of adverse effects can be increased when Infliximab is combined with Magrolimab. |
| Trastuzumab | The risk or severity of adverse effects can be increased when Trastuzumab is combined with Magrolimab. |
| Rituximab | The risk or severity of adverse effects can be increased when Rituximab is combined with Magrolimab. |
| Basiliximab | The risk or severity of adverse effects can be increased when Basiliximab is combined with Magrolimab. |
| Muromonab | The risk or severity of adverse effects can be increased when Muromonab is combined with Magrolimab. |
| Digoxin Immune Fab (Ovine) | The risk or severity of adverse effects can be increased when Digoxin Immune Fab (Ovine) is combined with Magrolimab. |
| Ibritumomab tiuxetan | The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Magrolimab. |
| Tositumomab | The risk or severity of adverse effects can be increased when Tositumomab is combined with Magrolimab. |
| Alemtuzumab | The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Magrolimab. |
| Capromab pendetide | The risk or severity of adverse effects can be increased when Capromab pendetide is combined with Magrolimab. |
| Efalizumab | The risk or severity of adverse effects can be increased when Efalizumab is combined with Magrolimab. |
| Antithymocyte immunoglobulin (rabbit) | The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Magrolimab. |
| Natalizumab | The risk or severity of adverse effects can be increased when Natalizumab is combined with Magrolimab. |
| Palivizumab | The risk or severity of adverse effects can be increased when Palivizumab is combined with Magrolimab. |
| Daclizumab | The risk or severity of adverse effects can be increased when Daclizumab is combined with Magrolimab. |
| Bevacizumab | The risk or severity of adverse effects can be increased when Bevacizumab is combined with Magrolimab. |
| Technetium Tc-99m arcitumomab | The risk or severity of adverse effects can be increased when Technetium Tc-99m arcitumomab is combined with Magrolimab. |
| Eculizumab | The risk or severity of adverse effects can be increased when Eculizumab is combined with Magrolimab. |
| Panitumumab | The risk or severity of adverse effects can be increased when Panitumumab is combined with Magrolimab. |
| Ranibizumab | The risk or severity of adverse effects can be increased when Ranibizumab is combined with Magrolimab. |
| Galiximab | The risk or severity of adverse effects can be increased when Galiximab is combined with Magrolimab. |
| Pexelizumab | The risk or severity of adverse effects can be increased when Pexelizumab is combined with Magrolimab. |
| Afelimomab | The risk or severity of adverse effects can be increased when Afelimomab is combined with Magrolimab. |
| Epratuzumab | The risk or severity of adverse effects can be increased when Epratuzumab is combined with Magrolimab. |
| Bectumomab | The risk or severity of adverse effects can be increased when Bectumomab is combined with Magrolimab. |
| Oregovomab | The risk or severity of adverse effects can be increased when Oregovomab is combined with Magrolimab. |
| IGN311 | The risk or severity of adverse effects can be increased when IGN311 is combined with Magrolimab. |
| Adecatumumab | The risk or severity of adverse effects can be increased when Adecatumumab is combined with Magrolimab. |
| Labetuzumab | The risk or severity of adverse effects can be increased when Labetuzumab is combined with Magrolimab. |
| Matuzumab | The risk or severity of adverse effects can be increased when Matuzumab is combined with Magrolimab. |
| Fontolizumab | The risk or severity of adverse effects can be increased when Fontolizumab is combined with Magrolimab. |
| Bavituximab | The risk or severity of adverse effects can be increased when Bavituximab is combined with Magrolimab. |
| CR002 | The risk or severity of adverse effects can be increased when CR002 is combined with Magrolimab. |
| Rozrolimupab | The risk or severity of adverse effects can be increased when Rozrolimupab is combined with Magrolimab. |
| Hepatitis B immune globulin | The risk or severity of adverse effects can be increased when Hepatitis B immune globulin is combined with Magrolimab. |
| Girentuximab | The risk or severity of adverse effects can be increased when Girentuximab is combined with Magrolimab. |
| Obiltoxaximab | The risk or severity of adverse effects can be increased when Obiltoxaximab is combined with Magrolimab. |
| XTL-001 | The risk or severity of adverse effects can be increased when XTL-001 is combined with Magrolimab. |
| NAV 1800 | The risk or severity of adverse effects can be increased when NAV 1800 is combined with Magrolimab. |
| Briakinumab | The risk or severity of adverse effects can be increased when Briakinumab is combined with Magrolimab. |
| Otelixizumab | The risk or severity of adverse effects can be increased when Otelixizumab is combined with Magrolimab. |
| AMG 108 | The risk or severity of adverse effects can be increased when AMG 108 is combined with Magrolimab. |
| Iratumumab | The risk or severity of adverse effects can be increased when Iratumumab is combined with Magrolimab. |
| Enokizumab | The risk or severity of adverse effects can be increased when Enokizumab is combined with Magrolimab. |
| Ramucirumab | The risk or severity of adverse effects can be increased when Ramucirumab is combined with Magrolimab. |
| Farletuzumab | The risk or severity of adverse effects can be increased when Farletuzumab is combined with Magrolimab. |
| Veltuzumab | The risk or severity of adverse effects can be increased when Veltuzumab is combined with Magrolimab. |
| Ustekinumab | The risk or severity of adverse effects can be increased when Ustekinumab is combined with Magrolimab. |
| Trastuzumab emtansine | The risk or severity of adverse effects can be increased when Trastuzumab emtansine is combined with Magrolimab. |
| PRO-542 | The risk or severity of adverse effects can be increased when PRO-542 is combined with Magrolimab. |
| TNX-901 | The risk or severity of adverse effects can be increased when TNX-901 is combined with Magrolimab. |
| Inotuzumab ozogamicin | The risk or severity of adverse effects can be increased when Inotuzumab ozogamicin is combined with Magrolimab. |
| RI 624 | The risk or severity of adverse effects can be increased when RI 624 is combined with Magrolimab. |
| Stamulumab | The risk or severity of adverse effects can be increased when MYO-029 is combined with Magrolimab. |
| CT-011 | The risk or severity of adverse effects can be increased when CT-011 is combined with Magrolimab. |
| Leronlimab | The risk or severity of adverse effects can be increased when Leronlimab is combined with Magrolimab. |
| Glembatumumab vedotin | The risk or severity of adverse effects can be increased when Glembatumumab vedotin is combined with Magrolimab. |
| Olaratumab | The risk or severity of adverse effects can be increased when Olaratumab is combined with Magrolimab. |
| IPH 2101 | The risk or severity of adverse effects can be increased when IPH 2101 is combined with Magrolimab. |
| TB-402 | The risk or severity of adverse effects can be increased when TB-402 is combined with Magrolimab. |
| Caplacizumab | The risk or severity of adverse effects can be increased when Caplacizumab is combined with Magrolimab. |
| IMC-1C11 | The risk or severity of adverse effects can be increased when IMC-1C11 is combined with Magrolimab. |
| Eldelumab | The risk or severity of adverse effects can be increased when Eldelumab is combined with Magrolimab. |